A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters

被引:77
作者
Mokrzycki, MH
Jean-Jerome, K
Rush, H
Zdunek, MP
Rosenberg, SO
机构
[1] Montefiore Med Ctr, Bronx, NY 10467 USA
[2] Albert Einstein Coll Med, Jacobi Med Ctr, Div Nephrol, Bronx, NY 10467 USA
关键词
tunneled cuffed catheters; thrombosis; chronic renal disease; dialysis access; fibrin sheath formation;
D O I
10.1046/j.1523-1755.2001.0590051935.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Minidose warfarin (1 mg/day) has been associated with a 74% reduction in the thrombosis rate of central venous catheters used in oncology patients. To determine the efficacy of minidose warfarin on late malfunction caused by thrombosis or fibrin sheath formation in tunneled, cuffed catheters (TCC) used for hemodialysis (HD), we performed a randomized, placebo-controlled trial. Methods. One hundred five chronic IID patients with TCCs were initially randomized. Of these, 85 (warfarin 41 and placebo 44) completed the first two weeks of the protocol and were followed for the first year of TCC life or until TCC removal. Results. Sixteen TCCs failed with late TCC malfunction, eight in each group. In a multivariate analysis, there was no significant effect of warfarin on thrombosis-free TCC survival or time to the first urokinase (UK) instillation for incipient thrombosis. The presence of a low hemoglobin (Hgb; < 10.5 g/dL) or a low international normalized ratio (INR; <1.00) was significantly associated with a higher risk of late TCC malfunction (RR 5.2 and 4.0, respectively), a higher risk of incipient TCC thrombosis requiring UK: (RR 2.0 and 2.8, respectively), and higher rates of UK dosing. Diabetics had a 3.6-fold higher risk of late TCC malfunction and a twofold higher risk of incipient thrombosis requiring UK, although these findings were not statistically significant. Aspirin use, race, age, number of hospitalizations, erythropoietin dose, intradialytic heparin dose, serum albumin, and the number of episodes of TCC-associated infection were not significantly associated with late TCC malfunction. Conclusions. Thrombosis prophylaxis using fixed minidose warfarin is not efficacious in TCCs used for HD. However, the present data suggest improved Tee survival in patients with an INR >1.00. Patients with diabetes and those with a low Hgb or INR have a higher risk of late TCC malfunction.
引用
收藏
页码:1935 / 1942
页数:8
相关论文
共 19 条
  • [1] VERY LOW-DOSES OF WARFARIN CAN PREVENT THROMBOSIS IN CENTRAL VENOUS CATHETERS - A RANDOMIZED PROSPECTIVE TRIAL
    BERN, MM
    LOKICH, JJ
    WALLACH, SR
    BOTHE, A
    BENOTTI, PN
    ARKIN, CF
    GRECO, FA
    HUBERMAN, M
    MOORE, C
    [J]. ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) : 423 - 428
  • [2] The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
    Besarab, A
    Bolton, WK
    Browne, JK
    Egrie, JC
    Nissenson, AR
    Okamoto, DM
    Schwab, SJ
    Goodkin, DA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) : 584 - 590
  • [3] DIAGNOSIS OF THROMBOSIS BY CATHETER PHLEBOGRAPHY AFTER PROLONGED CENTRAL VENOUS CATHETERIZATION
    BRISMAR, B
    HARDSTEDT, C
    JACOBSON, S
    [J]. ANNALS OF SURGERY, 1981, 194 (06) : 779 - 783
  • [4] Hemodialysis vascular access: Effect on urea kinetics and the dialysis prescription
    Butterly, DW
    Schwab, SJ
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 1996, 16 (01) : 45 - 51
  • [5] INTERNAL JUGULAR-VEIN CANNULATION WITH 2 SILICONE-RUBBER CATHETERS - A NEW AND SAFE TEMPORARY VASCULAR ACCESS FOR HEMODIALYSIS - 30 MONTHS EXPERIENCE
    CANAUD, B
    BERAUD, JJ
    JOYEUX, H
    MION, C
    [J]. ARTIFICIAL ORGANS, 1986, 10 (05) : 397 - 403
  • [6] Management of fibrin sheaths I: Percutaneous fibrin sheath stripping
    Crain, M
    [J]. SEMINARS IN DIALYSIS, 1998, 11 (06) : 336 - 341
  • [7] Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation - The AFASAK 2 Study
    Gullov, AL
    Koefoed, BG
    Petersen, P
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (12) : 1322 - 1328
  • [8] Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation
    Jaar, B
    Denis, A
    Viron, B
    Verdy, E
    Chamma, F
    Siohan, P
    Mignon, F
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 1997, 17 (05) : 399 - 405
  • [9] Koefoed BG, 1997, THROMB HAEMOSTASIS, V77, P845
  • [10] DOUBLE-BLIND RANDOMIZED TRIAL OF VERY-LOW-DOSE WARFARIN FOR PREVENTION OF THROMBOEMBOLISM IN STAGE-IV BREAST-CANCER
    LEVINE, M
    HIRSH, J
    GENT, M
    ARNOLD, A
    WARR, D
    FALANGA, A
    SAMOSH, M
    BRAMWELL, V
    PRITCHARD, KI
    STEWART, D
    GOODWIN, P
    [J]. LANCET, 1994, 343 (8902) : 886 - 889